TGFB1 and cardiovascular disorder: Pre-clinical studies suggested that treatment of LSKL or relevant tripeptide SRI31277 could be novel therapeutic strategies for various cardiovascular diseases,912 pulmonary diseases,913 renal diseases,914–916 nervous diseases,917,918 fibrotic diseases,919–921 wound healing,922,923 and tumors.924–926 Moreover, TSP-1 antisense oligonucleotides were successfully developed and applied to inhibit TGF-β activation in a rat model of mesangial proliferative glomerulonephritis, demonstrating a remarkable prevention against renal fibrosis.927